Defence Therapeutics Inc.
DTCFF · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $120 | $220 | $126 | $597 |
| G&A Expenses | $529 | $255 | $214 | $2,006 |
| SG&A Expenses | $783 | $255 | $214 | $433 |
| Sales & Mktg Exp. | $254 | $0 | $0 | -$1,573 |
| Other Operating Expenses | $124 | $153 | $169 | $96 |
| Operating Expenses | $1,028 | $627 | $509 | $1,125 |
| Operating Income | -$1,028 | $0 | $0 | -$1,125 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $76 | -$805 | -$607 | -$223 |
| Pre-Tax Income | -$952 | -$805 | -$607 | -$1,348 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$952 | -$805 | -$607 | -$1,348 |
| % Margin | – | – | – | – |
| EPS | -0.019 | -0.018 | -0.013 | -0.03 |
| % Growth | -9% | -33.1% | 55.1% | – |
| EPS Diluted | -0.019 | -0.018 | -0.013 | -0.03 |
| Weighted Avg Shares Out | 49,213 | 45,503 | 45,503 | 45,503 |
| Weighted Avg Shares Out Dil | 49,213 | 45,503 | 45,503 | 45,503 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $83 | $109 | $108 | $149 |
| Depreciation & Amortization | $18 | $18 | $18 | $49 |
| EBITDA | -$851 | -$678 | -$481 | -$1,151 |
| % Margin | – | – | – | – |